The Merck Access Program for RENFLEXIS® (infliximab-abda)
Before prescribing RENFLEXIS, please read the accompanying Prescribing Information including the Boxed Warning about serious infections and malignancies. The Medication Guide also is available.

WELCOME TO

THE MERCK ACCESS PROGRAM

ARE YOU A US HEALTH CARE PROFESSIONAL?
YES
NO

The Merck Access Program for RENFLEXIS® (infliximab-abda)

THE MERCK ACCESS PROGRAM FOR RENFLEXIS

Can help answer questions about:
  • Benefit investigations
  • Billing and coding
  • Co-pay assistance for eligible patients
  • Prior authorizations and appeals
  • Referral to the Merck Patient Assistance Program for eligibility determination (provided through the Merck Patient Assistance Program, Inc.)
Enrollment Form for The Merck Access Program for RENFLEXIS® (infliximab-abda)

Merck’s Response to Coronavirus (COVID-19)

During this unprecedented time, Merck is committed to ensuring our medicines reach our patients and customers. If you have concerns that your patient may have lost their insurance coverage due to the COVID-19 pandemic or may not be able to afford their medication, we encourage you to call The Merck Access Program.

For more details about Merck’s response to coronavirus, visit our COVID-19 information page.

Now Available: Electronic Enrollment Form with E-Signature

   

The page you are looking for is currently unavailable - please check back later!